BACKGROUND & AIMS: The combination of pegylated interferon (IFN) α and ribavirin (RBV) is the standard therapy for patients with chronic HCV infection. However, it produces a sustained virologic response (SVR) in only half of the treated individuals and is associated with significant side effects. Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNλ3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV. We sought to determine whether IL28B was capable of inhibiting HCV replication and to determine the pathway by which IL28B exhibits anti-HCV activity. METHODS: Using the full-length HCV replicon OR6 and the infectious HCV clones JFH1 and Jc1, we assessed the anti-HCV effect of IL28B on HCV and characterized the key steps of the JAK-STAT pathway by real time PCR, luciferase assay, and Western blot. Finally, we evaluated the anti-HCV effect of IL28B in the presence of JAK-STAT pathway inhibitors such as blocking antibodies, a pharmacological inhibitor, and siRNAs. RESULTS: We found that IL28B inhibits HCV replication in a dose- and time-dependent manner. Like IFNα, IL28B induces the phosphorylation of STAT1 and STAT2, ISRE-driven transcription, and expression of known ISGs. The anti-HCV effects of IL28A, IL28B, and IL29 were abrogated by an IL10R2 blocking antibody, a pharmacological inhibitor of JAK1/TYK2, and by siRNA against IL28R1, STAT1, STAT2, and IRF9. CONCLUSIONS: Our data demonstrate that IL28A, IL28B, and IL29 signal through the JAK-STAT pathway to inhibit HCV. These data suggest possible applications of new approaches in HCV treatment.
BACKGROUND & AIMS: The combination of pegylated interferon (IFN) α and ribavirin (RBV) is the standard therapy for patients with chronic HCV infection. However, it produces a sustained virologic response (SVR) in only half of the treated individuals and is associated with significant side effects. Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNλ3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV. We sought to determine whether IL28B was capable of inhibiting HCV replication and to determine the pathway by which IL28B exhibits anti-HCV activity. METHODS: Using the full-length HCV replicon OR6 and the infectious HCV clones JFH1 and Jc1, we assessed the anti-HCV effect of IL28B on HCV and characterized the key steps of the JAK-STAT pathway by real time PCR, luciferase assay, and Western blot. Finally, we evaluated the anti-HCV effect of IL28B in the presence of JAK-STAT pathway inhibitors such as blocking antibodies, a pharmacological inhibitor, and siRNAs. RESULTS: We found that IL28B inhibits HCV replication in a dose- and time-dependent manner. Like IFNα, IL28B induces the phosphorylation of STAT1 and STAT2, ISRE-driven transcription, and expression of known ISGs. The anti-HCV effects of IL28A, IL28B, and IL29 were abrogated by an IL10R2 blocking antibody, a pharmacological inhibitor of JAK1/TYK2, and by siRNA against IL28R1, STAT1, STAT2, and IRF9. CONCLUSIONS: Our data demonstrate that IL28A, IL28B, and IL29 signal through the JAK-STAT pathway to inhibit HCV. These data suggest possible applications of new approaches in HCV treatment.
Authors: Leiliang Zhang; Stella Y Lee; Galina V Beznoussenko; Peter J Peters; Jia-Shu Yang; Hui-ya Gilbert; Abraham L Brass; Stephen J Elledge; Stuart N Isaacs; Bernard Moss; Alexander Mironov; Victor W Hsu Journal: Proc Natl Acad Sci U S A Date: 2008-12-24 Impact factor: 11.205
Authors: Andri Rauch; Zoltán Kutalik; Patrick Descombes; Tao Cai; Julia Di Iulio; Tobias Mueller; Murielle Bochud; Manuel Battegay; Enos Bernasconi; Jan Borovicka; Sara Colombo; Andreas Cerny; Jean-François Dufour; Hansjakob Furrer; Huldrych F Günthard; Markus Heim; Bernard Hirschel; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; Andrea Witteck; Jacques S Beckmann; Thomas Berg; Sven Bergmann; Francesco Negro; Amalio Telenti; Pierre-Yves Bochud Journal: Gastroenterology Date: 2010-01-11 Impact factor: 22.682
Authors: Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein Journal: Nature Date: 2009-08-16 Impact factor: 49.962
Authors: Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George Journal: Nat Genet Date: 2009-09-13 Impact factor: 38.330
Authors: Svetlana Marukian; Christopher T Jones; Linda Andrus; Matthew J Evans; Kimberly D Ritola; Edgar D Charles; Charles M Rice; Lynn B Dustin Journal: Hepatology Date: 2008-12 Impact factor: 17.425
Authors: David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington Journal: Nature Date: 2009-10-08 Impact factor: 49.962
Authors: Chuanlong Zhu; Fei Xiao; Jian Hong; Kun Wang; Xiao Liu; Dachuan Cai; Dahlene N Fusco; Lei Zhao; Soung Won Jeong; Cynthia Brisac; Pattranuch Chusri; Esperance A Schaefer; Hong Zhao; Lee F Peng; Wenyu Lin; Raymond T Chung Journal: J Virol Date: 2015-04-15 Impact factor: 5.103
Authors: Hong Zhao; Wenyu Lin; Kattareeya Kumthip; Du Cheng; Dahlene N Fusco; Oliver Hofmann; Nikolaus Jilg; Andrew W Tai; Kaku Goto; Leiliang Zhang; Winston Hide; Jae Young Jang; Lee F Peng; Raymond T Chung Journal: J Hepatol Date: 2011-08-31 Impact factor: 25.083
Authors: Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos Journal: World J Gastroenterol Date: 2014-03-21 Impact factor: 5.742